|Biotech Due Diligence||
It has been awhile, so if you haven't explored my Sarepta Therapeutics SRPT resource page about the company, Duchenne muscular dystrophy (DMD), their drug eteplirsen as well as competitors, please do. One of the features is a collection of coverage of this story, from both the investor and patient/community perspectives. This post will feature a round-up of recent relevant content as we await the next updates from the company.
PS - check the Twitter folks who provided these links, all are key follows for those interested in this area.
PPS - as always, inclusion of a link here does not imply I endorse or agree with the views of the authors
RNA and Oligonucleotide Therapeutics
April 10 - 13, 2013
Cold Spring Harbor Laboratory (CSHL)
Conference homepage link
Ryszard Kole, Sarepta Therapeutics
Adrian Krainer, Cold Spring Harbor Laboratory
Art Krieg, RaNA Therapeutics
Bruce Sullenger, Duke University
There was a great deal of discussion around this conference, and particularly the data presentation by GSK/Prosensa for their Duchenne Muscular Dystrophy DMD drug drisapersen. This drug is of course the key competitor to eteplirsen from Sarepta Therapeutics SRPT. Key links and info are archived in this post.